Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer

Research output: Contribution to journalJournal articleResearchpeer-review

Samuel R Denmeade, Carsten M Jakobsen, Samuel Janssen, Saeed R Khan, Elizabeth S Garrett, Hans Lilja, S Brogger Christensen, John T Isaacs

Standard anti-proliferative chemotherapy is relatively ineffective against slowly proliferating androgen-independent prostate cancer cells within metastatic sites. In contrast, the lipophilic cytotoxin thapsigargin, which causes apoptosis by disrupting intracellular free Ca2+ levels, is effective against both proliferative and quiescent (i.e., G0-arrested) cells. However, thapsigargin's mechanism of action indicates that it is unlikely to be selective for cancer cells or prostate cells.
Original languageEnglish
JournalNational Cancer Institute. Journal (Online)
Issue number13
Pages (from-to)990-1000
Number of pages11
Publication statusPublished - 2 Jul 2003

    Research areas

  • Animals, Antineoplastic Agents, Disease Models, Animal, Humans, Hydrolysis, Male, Mice, Mice, Nude, Prodrugs, Prostate-Specific Antigen, Prostatic Neoplasms, Thapsigargin, Transplantation, Heterologous, Treatment Outcome

ID: 44569411